Drug intelligence / Profile preview

ADGEXG

Development stage: Preclinical
Lead developer: Adagene
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

ADGEXG is a bispecific antibody developed by Adagene for use in immuno-oncology. It is part of Adagene's fully human antibody platforms, such as Adaptor and NeoEP, which are designed for antibody engineering in cancer and immunology. WuXi Venture Fund provided Series A funding to Adagene to support the development of these platforms and drugs like ADGEXG.

Beyond the preview

Go deeper on ADGEXG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADGEXG.

Explore the full profile